{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:15:33Z","timestamp":1793913333423,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17bk0104070h0001\/18bk0104070h0002\/19bk0104070h0003 \/ 20bk01041h0001\/21bk0104109h0002"],"award-info":[{"award-number":["17bk0104070h0001\/18bk0104070h0002\/19bk0104070h0003 \/ 20bk01041h0001\/21bk0104109h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21be0804004h0001"],"award-info":[{"award-number":["21be0804004h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12185-022-03408-7","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T17:02:37Z","timestamp":1659200557000},"page":"754-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease"],"prefix":"10.1007","volume":"116","clinical-trial-number":[{"clinical-trial-number":"umin000032819","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-2894","authenticated-orcid":false,"given":"Tokiko","family":"Nagamura-Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Nagamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"3408_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.20.00619","volume":"39","author":"R Reshef","year":"2021","unstructured":"Reshef R, Saber W, Bola\u00f1os-Meade J, Chen G, Chen Y-B, Ho V, et al. Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study. J Clin Oncol. 2021;39:1878\u201387.","journal-title":"J Clin Oncol"},{"key":"3408_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"A Harris","year":"2016","unstructured":"Harris A, Young R, Devine S, Hogan W, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3408_CR3","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u201367.","journal-title":"Lancet Haematol"},{"key":"3408_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.0300-9475.2004.01483.x","volume":"60","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc K, Rasmusson I, G\u00f6therstrom C, Seidel C, Sundberg B, Sundin M, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol. 2004;60:307\u201315.","journal-title":"Scand J Immunol"},{"key":"3408_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579\u201386.","journal-title":"Lancet"},{"key":"3408_CR6","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","volume":"3","author":"S Hashmi","year":"2016","unstructured":"Hashmi S, Ahmed M, Murad M, Litzow M, Adams R, Ball L, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3:e45-52.","journal-title":"Lancet Haematol"},{"key":"3408_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439\u201341.","journal-title":"Lancet"},{"key":"3408_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.15749","volume":"185","author":"A Galleu","year":"2019","unstructured":"Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019;185:89\u201392.","journal-title":"Br J Haematol"},{"key":"3408_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/ten.tea.2009.0500","volume":"16","author":"H Agata","year":"2010","unstructured":"Agata H, Asahina I, Watanabe N, Ishii Y, Kubo N, Ohshima S, et al. Characteristic change and loss of in vivo osteogenic abilities of human bone marrow stromal cells during passage. Tissue Eng Part A. 2010;16:663\u201373.","journal-title":"Tissue Eng Part A"},{"key":"3408_CR10","doi-asserted-by":"crossref","unstructured":"Nagamura-Inoue T, Nagamura F. Umbilical cord blood and cord tissue bank as a source for allogeneic use. IntechOpen. 2021. pp. 31\u201355 (Chapter 3).","DOI":"10.5772\/intechopen.91649"},{"key":"3408_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12185-009-0377-3","volume":"90","author":"I Ishige","year":"2009","unstructured":"Ishige I, Nagamura-Inoue T, Honda MJ, Harnprasopwat R, Kido M, Sugimoto M, et al. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton\u2019s jelly explants of human umbilical cord. Int J Hematol. 2009;90:261\u20139.","journal-title":"Int J Hematol"},{"key":"3408_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12185-015-1844-7","volume":"102","author":"H He","year":"2015","unstructured":"He H, Nagamura-Inoue T, Takahashi A, Mori Y, Yamamoto Y, Shimazu T, et al. Immunosuppressive properties of Wharton\u2019s jelly-derived mesenchymal stromal cells in vitro. Int J Hematol. 2015;102:368\u201378.","journal-title":"Int J Hematol"},{"key":"3408_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jcyt.2015.03.604","volume":"17","author":"T Shimazu","year":"2015","unstructured":"Shimazu T, Mori Y, Takahashi A, Tsunoda H, Tojo A, Nagamura-Inoue T. Serum- and xeno-free cryopreservation of human umbilical cord tissue as mesenchymal stromal cell source. Cytotherapy. 2015;17:593\u2013600.","journal-title":"Cytotherapy"},{"key":"3408_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/ten.tec.2014.0385","volume":"21","author":"Y Mori","year":"2015","unstructured":"Mori Y, Ohshimo J, Shimazu T, He H, Takahashi A, Yamamoto Y, et al. Improved explant method to isolate umbilical cord-derived mesenchymal stem cells and their immunosuppressive properties. Tissue Eng Part C Methods. 2015;21:367\u201372.","journal-title":"Tissue Eng Part C Methods"},{"key":"3408_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202000558","volume":"16","author":"H Kurogi","year":"2021","unstructured":"Kurogi H, Takahashi A, Isogai M, Sakumoto M, Takijiri T, Hori A, et al. Umbilical cord derived mesenchymal stromal cells in microcarrier based industrial scale culture sustain the immune regulatory functions. Biotechnol J. 2021;16: e2000558.","journal-title":"Biotechnol J"},{"key":"3408_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686356","volume":"12","author":"H He","year":"2021","unstructured":"He H, Takahashi A, Mukai T, Hori A, Narita M, Tojo A, et al. The immunomodulatory effect of triptolide on mesenchymal stromal cells. Front Immunol. 2021;12: 686356.","journal-title":"Front Immunol"},{"key":"3408_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.leukres.2009.03.047","volume":"33","author":"M Narita","year":"2009","unstructured":"Narita M, Watanabe N, Yamahira A, Hashimoto S, Tochiki N, Saitoh A, et al. A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 2009;33:1224\u201332.","journal-title":"Leuk Res"},{"key":"3408_CR18","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3408_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transplant."},{"key":"3408_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","volume":"20","author":"J Kurtzberg","year":"2014","unstructured":"Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014;20:229\u201335.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3408_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/1744666X.2016.1208086","volume":"13","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Algeri M, Trevisan V, Bertaina A. Remestemcel-L for the treatment of graft versus host disease. Expert Rev Clin Immunol. 2017;13:43\u201356.","journal-title":"Expert Rev Clin Immunol"},{"key":"3408_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","volume":"103","author":"K Muroi","year":"2016","unstructured":"Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study. Int J Hematol. 2016;103:243\u201350.","journal-title":"Int J Hematol"},{"key":"3408_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12185-013-1399-4","volume":"98","author":"K Muroi","year":"2013","unstructured":"Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I\/II study. Int J Hematol. 2013;98:206\u201313.","journal-title":"Int J Hematol"},{"key":"3408_CR24","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","volume":"56","author":"M Murata","year":"2021","unstructured":"Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, et al. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplant. 2021;56:2355\u201366.","journal-title":"Bone Marrow Transplant"},{"key":"3408_CR25","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1097\/TP.0b013e31821aba18","volume":"91","author":"KH Wu","year":"2011","unstructured":"Wu KH, Chan CK, Tsai C, Chang YH, Sieber M, Chiu TH, et al. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation. 2011;91:1412\u20136.","journal-title":"Transplantation"},{"key":"3408_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcyt.2021.09.014","volume":"24","author":"L Ding","year":"2022","unstructured":"Ding L, Han DM, Zheng XL, Yan HM, Xue M, Liu J, et al. Infusion of haploidentical hematopoietic stem cells combined with mesenchymal stem cells for treatment of severe aplastic anemia in adult patients yields curative effects. Cytotherapy. 2022;24:205\u201312.","journal-title":"Cytotherapy"},{"key":"3408_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41598-020-80531-7","volume":"11","author":"Y Zu","year":"2021","unstructured":"Zu Y, Zhou J, Fu Y, Fang B, Liu X, Zhang Y, et al. Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. Sci Rep. 2021;11:253.","journal-title":"Sci Rep"},{"key":"3408_CR28","first-page":"225","volume":"3","author":"IB Resnick","year":"2013","unstructured":"Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225\u201338.","journal-title":"Am J Blood Res"},{"key":"3408_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.bbmt.2008.06.016","volume":"14","author":"L Boissel","year":"2008","unstructured":"Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008;14:1031\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3408_CR30","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1073\/pnas.1016257108","volume":"108","author":"P Vacca","year":"2011","unstructured":"Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E, et al. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci USA. 2011;108:2402\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3408_CR31","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1073\/pnas.0611098104","volume":"104","author":"DB Keskin","year":"2007","unstructured":"Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16\u2212 NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA. 2007;104:3378\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3408_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/iji.12523","volume":"48","author":"K Bogunia-Kubik","year":"2021","unstructured":"Bogunia-Kubik K, Lacina P. Non-KIR NK cell receptors: role in transplantation of allogeneic haematopoietic stem cells. Int J Immunogenet. 2021;48:157\u201371.","journal-title":"Int J Immunogenet"},{"key":"3408_CR33","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293\u2013301.","journal-title":"Blood"},{"key":"3408_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.bmt.1704165","volume":"32","author":"S Yamasaki","year":"2003","unstructured":"Yamasaki S, Henzan H, Ohno Y, Yamanaka T, Iino T, Itou Y, et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant. 2003;32:505\u201310.","journal-title":"Bone Marrow Transplant"},{"key":"3408_CR35","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","volume":"125","author":"DK Reichenbach","year":"2015","unstructured":"Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, et al. The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125:3183\u201392.","journal-title":"Blood"},{"key":"3408_CR36","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","volume":"130","author":"SW Choi","year":"2017","unstructured":"Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, et al. Vorinostat plus tacrolimus\/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017;130:1760\u20137.","journal-title":"Blood"},{"key":"3408_CR37","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.3389\/fimmu.2019.02338","volume":"10","author":"L Solan","year":"2019","unstructured":"Solan L, Kwon M, Carbonell D, Dorado N, Balsalobre P, Serrano D, et al. ST2 and REG3alpha as predictive biomarkers after haploidentical stem cell transplantation using post-transplantation high-dose cyclophosphamide. Front Immunol. 2019;10:2338.","journal-title":"Front Immunol"},{"key":"3408_CR38","doi-asserted-by":"publisher","first-page":"10740","DOI":"10.1038\/s41598-020-67563-9","volume":"10","author":"MO Gomzikova","year":"2020","unstructured":"Gomzikova MO, Aimaletdinov AM, Bondar OV, Starostina IG, Gorshkova NV, Neustroeva OA, et al. Immunosuppressive properties of cytochalasin B-induced membrane vesicles of mesenchymal stem cells: comparing with extracellular vesicles derived from mesenchymal stem cells. Sci Rep. 2020;10:10740.","journal-title":"Sci Rep"},{"key":"3408_CR39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1089\/scd.2011.0025","volume":"21","author":"H Smith","year":"2012","unstructured":"Smith H, Whittall C, Weksler B, Middleton J. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev. 2012;21:476\u201386.","journal-title":"Stem Cells Dev"},{"key":"3408_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575488","volume":"11","author":"M Cruz-Barrera","year":"2020","unstructured":"Cruz-Barrera M, Florez-Zapata N, Lemus-Diaz N, Medina C, Galindo CC, Gonzalez-Acero LX, et al. Integrated analysis of transcriptome and secretome from umbilical cord mesenchymal stromal cells reveal new mechanisms for the modulation of inflammation and immune activation. Front Immunol. 2020;11: 575488.","journal-title":"Front Immunol"},{"key":"3408_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10517-021-05373-3","volume":"172","author":"YL Zhang","year":"2021","unstructured":"Zhang YL, Qiao SK, Xing LN, Guo XN, Ren JH. Mesenchymal stem cells enhance chemotaxis of activated T cells through the CCL2-CCR2 axis in vitro. Bull Exp Biol Med. 2021;172:263\u20139.","journal-title":"Bull Exp Biol Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03408-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03408-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03408-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:20:14Z","timestamp":1666574414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03408-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3408"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03408-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was partially supported by the joint research study of the University of Tokyo with Rohto Pharmaceutical Co. Ltd. in the development of culture medium and processing (December 2014, December to March 2020) and the joint study of the University of Tokyo with Human Life Cord Japan Inc. in the development of banking and clinical application (September 2017\u2013). Nagamura-Inoue is the senior medical advisor of Human Life Cord Japan Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}